Remedy Robotics Raises $62 Million to Take Stroke-Treatment Robot to Trials
Remedy Robotics raised a $62 million Series B led by DCVC to fund a University of California trial of its N1 robot and work toward FDA approval.

Remedy Robotics, a San Francisco company building robots that perform procedures inside blood vessels, has raised $62 million in a Series B round led by venture firm DCVC, the company announced Nov. 16. The money will pay for a planned pivotal clinical trial with the University of California and for work toward approval from the Food and Drug Administration (FDA) to use the system in neurovascular procedures, such as treating stroke.
The company’s product, the N1 System, is still in development. Remedy said it is not for sale or approved for clinical use anywhere.
Who invested
New backers in the round include UC Investments, the University of California’s investment office, as well as Skip Capital and Hostplus, which the company described as one of Australia’s largest pension funds. Existing investors Build Collective (Tony Fadell’s firm), Blackbird, Divergent Capital and KdT Ventures put in more money. Remedy did not disclose a valuation.
James Hardiman, a general partner at DCVC, said in the announcement that the firm sees Remedy as part of a new generation of medical robotics and physical AI companies.
What the N1 System does
Endovascular procedures are treatments carried out from inside the blood vessels. According to Remedy, the N1 System uses machine learning to study scans taken before an operation, rehearse a case in advance and line up 3D and 2D images during the procedure, and it can carry out a full procedure with a robot. The company says it is built to be run by a doctor in the room, by a doctor at a distance, or on its own.
Remedy says it works with more than 100 hospitals around the world. In October 2025, it announced what it called the world’s first remote neurointerventional procedures with the N1 System. The company also says it holds 48 patents on the platform.
Where the money goes
- A planned pivotal clinical trial run across the University of California network. Co-founder and CTO Jake Sganga said the company has worked with UC clinicians since 2021.
- Progress toward FDA approval for neurovascular intervention.
- Placing prototype N1 Systems with clinical partners, including SVIN Mission Thrombectomy and the Australian Stroke Alliance.
- Further development of the system’s AI and autonomous features, including what Sganga called “full autonomy.”
What it means for patients and hospitals
The company’s pitch is about access. CEO and co-founder Dr. David Bell said only a small number of hospitals can offer this kind of treatment, and that care is often delayed even where it exists. Remedy cites figures that cardiovascular disease, including stroke and heart attack, kills nearly 20 million people a year, that stroke alone costs about $891 billion a year worldwide, and that just 2.8 percent of eligible stroke patients around the world can get endovascular treatment.
What to watch next
Remedy has not given dates for the start of its pivotal trial or for an FDA filing. The next milestones are the launch of the UC trial and the rollout of prototype systems to partner hospitals. More on how rounds like this one are structured is in our explainer on startup funding rounds from pre-seed to Series C.
Source: PR Newswire


